place

Theresianum Gymnasium Mainz

Buildings and structures in MainzGerman school stubsGymnasiums in GermanySchools in Rhineland-Palatinate

Theresianum Gymnasium (for short: Theresianum or TH) is a private all-day secondary and high school located in Mainz, Germany. It was founded in 1927 by the Johannesbund e.V. The high school is a Catholic school and is part of Schulgesellschaft Sankt Martinus. This does not mean that the school does not accept students with a different religion. Students have the opportunity to achieve the highest academic high school degree, the Abitur after year 12 while they enroll in school for year 5. Theresianum prepares young people for the future with an innovative concept, including modern spaces and equipment for learning. "Healthy learning needs diversity so children and young people can concentrate better and feel comfortable in a healthy learning environment." (analogously translated from German website)

Excerpt from the Wikipedia article Theresianum Gymnasium Mainz (License: CC BY-SA 3.0, Authors).

Theresianum Gymnasium Mainz
Oberer Laubenheimer Weg, Mainz Oberstadt (Oberstadt)

Geographical coordinates (GPS) Address Website External links Nearby Places
placeShow on map

Wikipedia: Theresianum Gymnasium MainzContinue reading on Wikipedia

Geographical coordinates (GPS)

Latitude Longitude
N 49.9836 ° E 8.2848 °
placeShow on map

Address

Theresianum

Oberer Laubenheimer Weg 58
55131 Mainz, Oberstadt (Oberstadt)
Rhineland-Palatinate, Germany
mapOpen on Google Maps

Website
theresianum-mainz.de

linkVisit website

linkWikiData (Q18394108)
linkOpenStreetMap (27438617)

Share experience

Nearby Places

BioNTech
BioNTech

BioNTech SE ( bee-ON-tek; or bye-ON-tek short for Biopharmaceutical New Technologies) is a German biotechnology company based in Mainz that develops and manufactures active immunotherapies for patient-specific approaches to the treatment of diseases. It develops pharmaceutical candidates based on messenger ribonucleic acid (mRNA) for use as individualized cancer immunotherapies, as vaccines against infectious diseases and as protein replacement therapies for rare diseases, and also engineered cell therapy, novel antibodies and small molecule immunomodulators as treatment options for cancer. The company has developed an mRNA-based human therapeutic for intravenous administration to bring individualized mRNA-based cancer immunotherapy to clinical trials and to establish its own manufacturing process.In 2020, BioNTech, partnering with Pfizer for testing and logistics, developed the RNA vaccine BNT162b2 for preventing COVID-19 infections, which at the time offered a 91% efficacy in preventing confirmed COVID-19 occurring at least 7 days after the second dose of vaccine. On 2 December 2020, temporary HMR authorization was granted by the United Kingdom government for BNT162b2 vaccinations within the United Kingdom. It was the first mRNA vaccine ever authorized. Some days later the vaccine also received an emergency approval in the United States, Canada and Switzerland. On 21 December 2020, the European Commission approved BioNTech/Pfizer's coronavirus vaccine in accordance with the positive recommendation of the European Medicines Agency (EMA).